Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Computational Investigation of Endophytic Fungal (Penicillium citrinum CGJ-C2) Compound and Its In-silico Derivatives for the Inhibition of RNA-Dependent RNA Polymerase of SARS-CoV-2

Author(s): Jagadeesha Poyya, Ananda Danagoudar, Chandrasekhar G Joshi*, Ajay S Khandagale and Raju Narayanappa Govinda

Volume 4, Issue 4, 2023

Published on: 16 October, 2023

Article ID: e161023222258 Pages: 11

DOI: 10.2174/0126667975260543231011113718

Price: $65

Abstract

Background: The SARS-CoV2 was responsible for the pandemic situation across the world. SARS-CoV2 is an RNA virus, and its replication depends on RNA Dependent RNA Polymerase (RdRp). Hence, blocking of RdRP would be an alternative strategy to inhibit the virus multiplication without affecting the host physiology.

Objective: The current study investigated the inhibitory effect of bioactive compound F3 isolated from P. citrinum CGJ-C2 and its in-silico derivates against RdRp of COVID using computational methods.

Methods: Compound F3 and its derivatives were generated computationally, and the crystal structure of RdRp was processed prior to docking. The RdRp and the bioactive compounds were docked using Glide with three levels of precisions. Post-docking MMGBSA analysis and Molecular Dynamic simulations were carried out to study the stability of the docking interactions.

Results: Based on the Glide XP score and MMGBSA analysis of fifteen ligands, three leads were selected, compound F3 (-8.655 Kcal/mol), D-1(-8.295 Kcal/mol), and D-14(-8.262 Kcal/mol). These leads (Compound F3, D-1, and D-14) were further evaluated using molecular dynamics (MD) simulation. MD simulations studies showed the stable bonding interaction between LYS500 and ARG569 residues of RdRp with the three lead molecules.

Conclusion: Our study highlighted the potential of compounds in terms of binding, interaction stability, and structural integrity. Therefore, these leads can be chosen for further studies in in vitro and in vivo to develop a novel anti-SARS-CoV2 agent with minimal side effects.

Graphical Abstract

[1]
Kushwaha PK, Kumari N, Nayak S, Kishor K, Sharon A. Structural basis for the understanding of entry inhibitors against SARS viruses. Curr Med Chem 2022; 29(4): 666-81.
[http://dx.doi.org/10.2174/0929867328666210514122418] [PMID: 33992054]
[2]
Chen J, Vullikanti A, Santos J, et al. Epidemiological and economic impact of COVID-19 in the US. Sci Rep 2021; 11(1): 20451.
[http://dx.doi.org/10.1038/s41598-021-99712-z] [PMID: 34650141]
[3]
Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol 2020; 883: 173375.
[http://dx.doi.org/10.1016/j.ejphar.2020.173375] [PMID: 32682788]
[4]
Neagu M, Constantin C, Surcel M. Testing antigens, antibodies, and immune cells in COVID-19 as a public health topic—experience and outlines. Int J Environ Res Public Health 2021; 18(24): 13173.
[http://dx.doi.org/10.3390/ijerph182413173] [PMID: 34948782]
[5]
Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19(7): 409-24.
[http://dx.doi.org/10.1038/s41579-021-00573-0] [PMID: 34075212]
[6]
Wilson N, Mansoor OD, Boyd MJ, Kvalsvig A, Baker MG. We should not dismiss the possibility of eradicating COVID-19: Comparisons with smallpox and polio. BMJ Glob Health 2021; 6(8): e006810.
[http://dx.doi.org/10.1136/bmjgh-2021-006810] [PMID: 34373261]
[7]
Guruprasad L. Human SARS CoV‐2 spike protein mutations. Proteins 2021; 89(5): 569-76.
[http://dx.doi.org/10.1002/prot.26042] [PMID: 33423311]
[8]
Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett 2022; 62: 128629.
[http://dx.doi.org/10.1016/j.bmcl.2022.128629] [PMID: 35182772]
[9]
Mengist HM, Dilnessa T, Jin T. Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem 2021; 9: 622898.
[http://dx.doi.org/10.3389/fchem.2021.622898] [PMID: 33889562]
[10]
Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart 2020; 106(19): 1503-11.
[http://dx.doi.org/10.1136/heartjnl-2020-317393] [PMID: 32737124]
[11]
Machitani M, Yasukawa M, Nakashima J, Furuichi Y, Masutomi K. RNA‐dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID‐19. Cancer Sci 2020; 111(11): 3976-84.
[http://dx.doi.org/10.1111/cas.14618] [PMID: 32805774]
[12]
Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019; 10(1): 2342.
[http://dx.doi.org/10.1038/s41467-019-10280-3] [PMID: 31138817]
[13]
Ahn DG, Choi JK, Taylor DR, Oh JW. Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Arch Virol 2012; 157(11): 2095-104.
[14]
Subissi L, Posthuma CC, Collet A, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci USA 2014; 111(37): E3900-9.
[http://dx.doi.org/10.1073/pnas.1323705111] [PMID: 25197083]
[15]
Ebrahimi KS, Ansari M, Hosseyni Moghaddam MS, et al. In silico investigation on the inhibitory effect of fungal secondary metabolites on RNA dependent RNA polymerase of SARS-CoV-II: A docking and molecular dynamic simulation study. Comput Biol Med 2021; 135: 104613.
[http://dx.doi.org/10.1016/j.compbiomed.2021.104613] [PMID: 34242870]
[16]
Tian L, Qiang T, Liang C, et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem 2021; 213: 113201.
[http://dx.doi.org/10.1016/j.ejmech.2021.113201] [PMID: 33524687]
[17]
Holman W, Holman W, McIntosh S, et al. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials 2021; 22(1): 561.
[http://dx.doi.org/10.1186/s13063-021-05538-5] [PMID: 34425873]
[18]
Zhang L, Zhou R. Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase. J Phys Chem B 2020; 124(32): 6955-62.
[http://dx.doi.org/10.1021/acs.jpcb.0c04198] [PMID: 32521159]
[19]
Gangadharan S, Ambrose JM, Rajajagadeesan A, et al. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach. J Infect Public Health 2022; 15(11): 1180-91.
[http://dx.doi.org/10.1016/j.jiph.2022.09.007] [PMID: 36240528]
[20]
Li E, Jiang L, Guo L, Zhang H, Che Y. Pestalachlorides A–C, antifungal metabolites from the plant endophytic fungus Pestalotiopsis adusta. Bioorg Med Chem 2008; 16(17): 7894-9.
[http://dx.doi.org/10.1016/j.bmc.2008.07.075] [PMID: 18694644]
[21]
Guo B, Dai JR, Ng S, et al. Cytonic acids A and B: Novel tridepside inhibitors of hCMV protease from the endophytic fungus Cytonaema species. J Nat Prod 2000; 63(5): 602-4.
[http://dx.doi.org/10.1021/np990467r] [PMID: 10843568]
[22]
Zhang G, Sun S, Zhu T, et al. Antiviral isoindolone derivatives from an endophytic fungus Emericella sp. associated with Aegiceras corniculatum. Phytochemistry 2011; 72(11-12): 1436-42.
[http://dx.doi.org/10.1016/j.phytochem.2011.04.014] [PMID: 21601895]
[23]
Selim K, Elkhateeb W, Tawila A, et al. Antiviral and antioxidant potential of fungal endophytes of Egyptian medicinal plants. Fermentation 2018; 4(3): 49.
[http://dx.doi.org/10.3390/fermentation4030049]
[24]
Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[25]
Harder E, Damm W, Maple J, et al. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 2016; 12(1): 281-96.https://pubs.acs.org/doi/10.1021/acs.jctc.5b00864
[http://dx.doi.org/10.1021/acs.jctc.5b00864]] [PMID: 26584231]
[26]
Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006; 49(21): 6177-96.
[http://dx.doi.org/10.1021/jm051256o] [PMID: 17034125]
[27]
Halgren TA, Murphy RB, Friesner RA, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47(7): 1750-9.
[http://dx.doi.org/10.1021/jm030644s] [PMID: 15027866]
[28]
Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47(7): 1739-49.
[http://dx.doi.org/10.1021/jm0306430] [PMID: 15027865]
[29]
Yin W, Luan X, Li Z, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol 2021; 28(3): 319-25.
[http://dx.doi.org/10.1038/s41594-021-00570-0] [PMID: 33674802]
[30]
Poyya J, Kumar DJ, Nagendra HG, Dinesh B, Aditya Rao SJ, Joshi CG. Receptor based virtual screening of potential novel inhibitors of tigar [TP53 (tumour protein 53)-induced glycolysis and apoptosis regulator. Med Hypotheses 2021; 156(Sep): 110683.
[http://dx.doi.org/10.1016/j.mehy.2021.110683] [PMID: 34583309]
[31]
Jacobson MP, Pincus DL, Rapp CS, et al. A hierarchical approach to all-atom protein loop prediction. Proteins 2004; 55(2): 351-67.
[http://dx.doi.org/10.1002/prot.10613] [PMID: 15048827]
[32]
Jacobson MP, Friesner RA, Xiang Z, Honig B. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 2002; 320(3): 597-608.
[http://dx.doi.org/10.1016/S0022-2836(02)00470-9] [PMID: 12096912]
[33]
Shaw DE. Desmond Maestro 2020 by DE Shaw Research. DE Shaw Research 2021.
[34]
Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A 2001; 105(43): 9954-60.
[http://dx.doi.org/10.1021/jp003020w]
[35]
Peng J, Zhang X, Du L, et al. Sorbicatechols A and B, antiviral sorbicillinoids from the marine-derived fungus Penicillium chrysogenum PJX-17. J Nat Prod 2014; 77(2): 424-8.
[http://dx.doi.org/10.1021/np400977e] [PMID: 24495078]
[36]
Zhang W, Tao J, Yang X, et al. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun 2014; 449(3): 307-12.
[http://dx.doi.org/10.1016/j.bbrc.2014.05.019] [PMID: 24845570]
[37]
Roy K. In silico modeling of drugs against coronaviruses: Computational tools and protocols.In:Methods in Pharmacology and Toxicology. New York: Springer 2021.https://link.springer.com
[http://dx.doi.org/10.1007/978-1-0716-1366-5]
[38]
Kawsar MA, Hosen MA, Ahmad S, El Bakri Y. Potential SARS-CoV-2 RdRp inhibitors of cytidine derivatives: Molecular docking, molecular dynamic simulations, ADMET, and POM analyses for the identification of pharmacophore sites. PLoS ONE 2022; 17(11): e0273256.
[39]
Ammarah U, Kumar A, Pal R, Bal NC, Misra G. Identification of new inhibitors against human Great wall kinase using in silico approaches. Sci Rep 2018; 8(1): 4894.
[http://dx.doi.org/10.1038/s41598-018-23246-0] [PMID: 29559668]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy